Two people can encounter the same respiratory pathogen and have very different experiences: one may barely notice it while another develops prolonged or severe disease. It is tempting to look for one explanation — a “strong” immune system, one gene or one lifestyle factor.
Human immune biology is not that simple. Twin studies show that some immune traits carry inherited signals while many measured immune differences are strongly shaped by non-heritable influences and accumulated exposure history. Modern host-genetic studies add another layer: inherited variants can influence susceptibility and severity for particular viruses, but they explain only part of the outcome.
Quick answer
If two healthy people catch the same respiratory virus, should their immune systems respond roughly the same way?
No. The pathogen matters, but so do the host and the context. Genetics can influence immune recognition and susceptibility, while age, prior immunity, health conditions, exposure history, viral factors and many non-heritable influences can change the response. None of these factors alone reliably predicts one person’s clinical course.
Key takeaways
- In a systems study of 210 healthy twins, many of 204 measured immune parameters were dominated by non-heritable influences; this describes specific immune traits, not all infectious-disease susceptibility.
- Twin and SNP-genotyped antiviral-antibody research shows that some epitope-selection traits are heritable, demonstrating that immune recognition can carry inherited structure.
- A large COVID-19 host-genetics meta-analysis found genetic associations with susceptibility and severity, but SNP-based heritability estimates were modest rather than destiny-like.
- A 2025 CRISPR study identified host-cell dependencies shared by multiple respiratory viruses; this is mechanistic evidence, not a clinical severity predictor.
- Current multi-virus evidence supports a layered model involving age, immune history, comorbidity, viral evolution and host biology rather than one universal “strong immune system” score.
The same pathogen does not meet the same host
“Same virus” is useful shorthand, but real exposures are rarely identical. People can encounter different doses, variants, routes and timing, and they bring different immune histories to the encounter.
That means disease severity begins as a virus–host interaction rather than a property of the virus alone or the person alone. The same named pathogen can therefore produce different outcomes without requiring one hidden master variable.
What the twin immune-system study actually measured
Brodin and colleagues profiled 210 healthy twins aged 8 to 82 and measured 204 immune parameters, including immune-cell frequencies, cytokine responses and serum proteins. Many of these measurements were dominated by non-heritable influences in the fitted analyses.
The study also compared monozygotic twins who differed in cytomegalovirus status and found that this exposure was associated with broad differences in immune measurements. That is strong evidence that immune systems adapt to accumulated exposures, but it does not mean every discordant twin difference was caused by lifestyle or that genes matter little for infection outcomes.
Genetics can shape what the immune system recognizes
A 2022 twin and SNP-genotyped study used high-throughput viral epitope profiling and found heritable features of antiviral antibody recognition, including multiple Epstein–Barr virus peptide responses and HLA-linked patterns.
This is a useful counterweight to simplistic “environment explains immunity” language. Inherited biology can influence which viral targets are recognized, while previous exposures and other non-heritable influences still shape the broader immune repertoire.
Host genetics can influence severity — without determining it
COVID-19 provided unusually large datasets for host-genetic research. A 2023 systematic review and meta-analysis included 96,817 cases and more than 6.4 million negative controls and identified genetic associations with both susceptibility and severity.
The reported SNP-based heritability estimates were modest. They help show that inherited variation contributes to population differences, but they do not support a personal genetic percentage or a rule that a specific variant determines whether an individual will become severely ill.
Shared host biology across different respiratory viruses
A 2025 genome-wide CRISPR study mapped host-cell factors used by nine respiratory viruses, including influenza, rhinovirus, RSV and several coronaviruses. Some host pathways were shared across viruses.
That work is important mechanistically because it shows that very different viruses can depend on common parts of host-cell biology. But a cell-dependency map is not the same as a clinical risk model. It cannot tell TwinPare or a consumer how severe their next infection will be.
Age, prior immunity and health history change the starting point
A current 2026 review across epidemic respiratory viruses highlights a broad set of risk and protective factors, including age, demographic characteristics, prior immune history, comorbidities, viral evolution and selected host-genetic susceptibility factors.
These factors can interact. Age can change immune function, prior infections or vaccination can alter immune memory, chronic disease can change physiological reserve, and a new viral variant can alter the challenge itself. A single-factor story is therefore rarely sufficient.
What identical twins can — and cannot — tell us
If genetically identical twins differ in an immune measurement or infection outcome, the difference shows that shared DNA was not sufficient to make the outcomes identical. It does not identify which exposure caused the divergence.
Twin designs are valuable because they help partition sources of population variation and sharpen causal questions. They are not a shortcut from discordance to “the environment caused it”, and they do not provide personal prognoses from heritability estimates.
Why “strong immune system” is a poor summary
Protection against infection and protection against severe inflammatory disease are not always the same biological problem. An effective response must control a pathogen while limiting damaging inflammation, and different immune pathways can matter at different stages.
That makes one universal immune-strength score scientifically misleading. A blood-cell count, antibody feature or wearable signal captures only a slice of the process and cannot substitute for clinical assessment.
TwinPare boundary
TwinPare Research can explain why susceptibility and severity vary between people and how twin research separates some inherited from nonshared influences. It should not turn those findings into personal infection-risk scoring.
TwinPare Health & Fitness must not diagnose viral infection, immune deficiency or likely disease severity from HRV, resting heart rate, temperature, sleep or other wearable data. Concerning symptoms or severe illness require appropriate medical assessment.
Source notes
The sources have been verified and editorially reviewed for this article. The limitations below show which level of conclusion the sources support.
- [brodin-immune-variation-twins-2015] Variation in the human immune system is largely driven by non-heritable influences Petter Brodin et al.. Cell, 2015. Evidence type: Systems-level immune phenotyping study in 210 healthy twins aged 8–82 Limitation: Across 204 measured immune parameters, many were dominated by non-heritable influences, and CMV discordance in monozygotic twins affected numerous immune measurements. The study concerns specific measured immune traits, not a universal statement that genes are unimportant for infection severity. PubMed PMC DOI
- [eshetie-covid-host-genetics-2023] Host genetic determinants of COVID-19 susceptibility and severity: A systematic review and meta-analysis Setegn Eshetie; Pastor Jullian; Beben Benyamin; S Hong Lee. Reviews in Medical Virology, 2023. Evidence type: Systematic review and meta-analysis of host genetic associations with COVID-19 susceptibility and severity Limitation: The analysis included 96,817 cases and more than 6.4 million negative controls. SNP-based heritability estimates were modest and virus-specific; they are not personal risk percentages and should not be generalized into one universal respiratory-virus score. PubMed DOI
- [soriaga-respiratory-host-dependencies-2025] Shared host genetic landscape of respiratory viral infection Leah B Soriaga et al.. Proceedings of the National Academy of Sciences, 2025. Evidence type: Genome-wide CRISPR host-factor study across nine human respiratory viruses Limitation: This work maps shared host-cell dependencies across respiratory viruses. It is mechanistic cell/host-dependency evidence, not a clinical study that predicts how sick an individual person will become. PubMed PMC DOI
- [respiratory-virus-risk-protective-factors-2026] Risk and Protective Factors for Infection, Severe Disease, and Mortality in Epidemic Respiratory Viruses Yang Zheng et al.. Allergy, 2026. Evidence type: 2026 review of risk and protective factors across epidemic respiratory viruses Limitation: Use as current multi-virus context for demographic, host, immune-history, comorbidity, viral-evolution and selected genetic factors. Review-level associations do not create an individual prognosis. PubMed DOI
Editorial source review
This section shows how the article's key factual claims are linked to the source.
Phrasings that require caution
- Do not describe one gene, immune marker or HLA variant as determining respiratory-virus severity.
- Do not convert heritability or SNP-based heritability into an individual genetic-risk percentage.
- Do not say non-heritable influence means lifestyle caused the difference.
- Do not say identical twins prove a specific exposure caused discordance.
- Do not use the 2025 CRISPR host-dependency study as a human clinical severity predictor.
- Do not equate antibody epitope patterns with complete protection or clinical immunity.
- Do not diagnose infection, immune deficiency or likely severity from wearables or TwinPare data.
- Do not provide individualized treatment, testing or return-to-activity instructions.
| ID | Claim | Source support | Caution |
|---|